Our Expertise Unrivaled. Our Dedication Unwavering.

BRI is powering discoveries in order to learn how to rebalance the immune system in all autoimmune and immune system diseases. Our ultimate goal is to achieve a healthy immune system for each individual.

As a world-renowned, non-profit research institute we advance science that will predict, prevent, reverse and cure diseases of the immune system. Our Centers for Discovery accelerate progress through laboratory breakthroughs in immunology that can be translated to clinical therapies.

BRI is a leader in collaborative initiatives and frequently partners with global research institutes to drive research forward and power possibilities.

Global Collaboration Leader

Immune Tolerance Network 

BRI leads the Immune Tolerance Network (ITN), a collaborative network for clinical research focused on the development of therapeutic approaches that lead to immune tolerance in asthma and allergy, autoimmune diseases such as type 1 diabetes and solid organ transplantation. Learn more about the ITN or visit immunetolerance.org

TrialNet

BRI leads Type 1 Diabetes TrialNet, an international network that conducts clinical studies that evaluate new approaches to preventing, delaying and reversing the progression of type 1 diabetes. TrialNet is conducting clinical trials with researchers from 17 clinical centers in the United States and six internationally. An additional 200 affiliated research sites are participating in the TrialNet network. Learn more about TrialNet (fact sheet).

BRI Fast Facts

First established as the Virginia Mason Research Center in 1956

  • Renamed in 2002 in recognition of the Benaroya family of Seattle
  • 29 Laboratories
  • 325+ Scientists and staff
  • $71 Million in annual research volume 

To learn more about BRI:

Research at BRI is conducted with the highest ethical standards and integrity. Our Research Conflicts of Interest Policy is an important component of our research quality program. We also respect your privacy as detailed in this Joint Notice of Privacy Practices.